Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

mDixon-Based Synthetic CT Generation for PET Attenuation Correction on Abdomen and Pelvis Jointly Using Transfer Fuzzy Clustering and Active Learning-Based Classification.

Qian P, Chen Y, Kuo JW, Zhang YD, Jiang Y, Zhao K, Helo RA, Friel H, Baydoun A, Zhou F, Heo JU, Avril N, Herrmann K, Ellis R, Traughber B, Jones RS, Wang S, Su KH, Muzic RF.

IEEE Trans Med Imaging. 2019 Aug 16. doi: 10.1109/TMI.2019.2935916. [Epub ahead of print]

PMID:
31425065
2.

Chemoradiotherapy-related carotid artery inflammation in head and neck cancer patients quantified by [18F]FDG PET/CT.

Chen X, Zheng Y, Tatsuoka C, Muzic RF Jr, Okoye CC, O'Donnell JK, Zidar D, Avril N, Oliveira GH, Liu H, Bucher J, Machtay M, Yao M, Dorth JA.

Oral Oncol. 2019 Jun;93:101-106. doi: 10.1016/j.oraloncology.2019.04.008. Epub 2019 May 1.

PMID:
31109689
3.

UTE-mDixon-based thorax synthetic CT generation.

Su KH, Friel HT, Kuo JW, Al Helo R, Baydoun A, Stehning C, Crisan AN, Traughber MS, Devaraj A, Jordan DW, Qian P, Leisser A, Ellis RJ, Herrmann KA, Avril N, Traughber BJ, Muzic RF Jr.

Med Phys. 2019 Aug;46(8):3520-3531. doi: 10.1002/mp.13574. Epub 2019 Jun 12.

PMID:
31063248
4.

Post-radiotherapy PET/CT for predicting treatment outcomes in head and neck cancer after postoperative radiotherapy.

Li Y, Awan MJ, Chang T, Lavertu P, Zender C, Rezaee R, Fowler N, Wasman J, Avril NE, Chen N, Machtay M, Yao M.

Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):794-800. doi: 10.1007/s00259-019-4272-8. Epub 2019 Jan 24.

PMID:
30680587
5.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A.

JAMA Oncol. 2017 Jan 1;3(1):58-66. doi: 10.1001/jamaoncol.2016.3049.

PMID:
27584578
6.

Altered glutamine metabolism in platinum resistant ovarian cancer.

Hudson CD, Savadelis A, Nagaraj AB, Joseph P, Avril S, DiFeo A, Avril N.

Oncotarget. 2016 Jul 5;7(27):41637-41649. doi: 10.18632/oncotarget.9317.

7.

FDG-PET imaging in hematological malignancies.

Valls L, Badve C, Avril S, Herrmann K, Faulhaber P, O'Donnell J, Avril N.

Blood Rev. 2016 Jul;30(4):317-31. doi: 10.1016/j.blre.2016.02.003. Epub 2016 Apr 16. Review.

8.

Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study.

Antunes J, Viswanath S, Rusu M, Valls L, Hoimes C, Avril N, Madabhushi A.

Transl Oncol. 2016 Apr;9(2):155-162. doi: 10.1016/j.tranon.2016.01.008.

9.

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

Avril S, Muzic RF Jr, Plecha D, Traughber BJ, Vinayak S, Avril N.

J Nucl Med. 2016 Feb;57 Suppl 1:34S-9S. doi: 10.2967/jnumed.115.157875. Review.

10.

Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors.

Sharma R, Kallur KG, Ryu JS, Parameswaran RV, Lindman H, Avril N, Gleeson FV, Lee JD, Lee KH, O'Doherty MJ, Groves AM, Miller MP, Somer EJ, Coombes CR, Aboagye EO.

J Nucl Med. 2015 Dec;56(12):1855-61. doi: 10.2967/jnumed.115.158253. Epub 2015 Sep 17.

11.

Whole-body positron emission tomography-magnetic resonance in breast cancer.

Sher A, Valls L, Muzic RF Jr, Plecha D, Avril N.

Semin Roentgenol. 2014 Oct;49(4):313-20. doi: 10.1053/j.ro.2014.08.001. Epub 2014 Aug 4. Review. No abstract available.

PMID:
25498228
12.

Positron emission tomography/magnetic resonance imaging of the breast.

Sher A, Vercher-Conejero JL, Muzic RF Jr, Avril N, Plecha D.

Semin Roentgenol. 2014 Oct;49(4):304-12. doi: 10.1053/j.ro.2014.04.011. Epub 2014 May 17. Review. No abstract available.

PMID:
25498227
13.

Management and organization of positron emission tomography/magnetic resonance imaging.

Devlin P, Sher A, Rubbert C, Jordan D, Faulhaber P, Avril N, Ros P.

Semin Roentgenol. 2014 Jul;49(3):271-4. doi: 10.1053/j.ro.2014.04.003. Epub 2014 Apr 18. Review. No abstract available.

PMID:
25497911
14.

Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.

Valls L, Hoimes C, Sher A, Hu L, Lee Z, Muzic R, Avril N.

Semin Roentgenol. 2014 Jul;49(3):238-41. doi: 10.1053/j.ro.2014.09.001. Epub 2014 Sep 16. No abstract available.

PMID:
25497908
15.

Letter from the guest editors.

Avril N, Ros PR.

Semin Roentgenol. 2014 Jul;49(3):236-7. doi: 10.1053/j.ro.2014.09.002. No abstract available.

PMID:
25497907
16.

Pelvis: normal variants and benign findings in FDG-PET/CT imaging.

Kohan A, Avril NE.

PET Clin. 2014 Apr;9(2):185-93. doi: 10.1016/j.cpet.2013.10.002. Epub 2013 Dec 10. Review.

PMID:
25030281
17.

GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study.

Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, Sobnack R, Colebrook S, Wan S, Halberrt G, Szysko T, Powles T, Avril N.

Mol Imaging Biol. 2014 Dec;16(6):888-95. doi: 10.1007/s11307-014-0754-z.

PMID:
24915934
18.

Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma.

Hudson CD, Hagemann T, Mather SJ, Avril N.

Cell Death Dis. 2014 Apr 10;5:e1160. doi: 10.1038/cddis.2014.125.

19.

Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume.

Rockall AG, Avril N, Lam R, Iannone R, Mozley PD, Parkinson C, Bergstrom D, Sala E, Sarker SJ, McNeish IA, Brenton JD.

Clin Cancer Res. 2014 May 15;20(10):2751-60. doi: 10.1158/1078-0432.CCR-13-2634. Epub 2014 Feb 26.

20.

Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.

Gaeta CM, Vercher-Conejero JL, Sher AC, Kohan A, Rubbert C, Avril N.

Q J Nucl Med Mol Imaging. 2013 Dec;57(4):352-66. Review.

21.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW.

Cancer Res. 2014 Feb 1;74(3):896-907. doi: 10.1158/0008-5472.CAN-13-1702. Epub 2013 Nov 27.

22.

Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.

Szlosarek PW, Luong P, Phillips MM, Baccarini M, Stephen E, Szyszko T, Sheaff MT, Avril N.

J Clin Oncol. 2013 Mar 1;31(7):e111-3. doi: 10.1200/JCO.2012.42.1784. Epub 2013 Jan 14. No abstract available.

PMID:
23319692
23.

New ways of assessing ovarian cancer response: metabolic imaging and beyond.

Rockall A, Munari A, Avril N.

Cancer Imaging. 2012 Sep 28;12:310-4. Review.

24.

The role of FDG-PET and bone marrow examination in lymphoma staging.

El-Najjar I, Barwick T, Avril N, Montoto S.

Ann Oncol. 2012 Sep;23 Suppl 10:x89-91.

PMID:
22987999
25.

The role of FDG-PET/CT in gynaecological cancers.

Rockall AG, Cross S, Flanagan S, Moore E, Avril N.

Cancer Imaging. 2012 Mar 5;12:49-65. doi: 10.1102/1470-7330.2012.0007. Review.

26.

Interleukin-6 as a therapeutic target in human ovarian cancer.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR.

Clin Cancer Res. 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. Epub 2011 Jul 27.

27.

Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.

Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds A, Powles T.

Clin Cancer Res. 2011 Sep 15;17(18):6021-8. doi: 10.1158/1078-0432.CCR-10-3309. Epub 2011 Jul 8.

28.

Gynecological cancers.

Avril N, Gourtsoyianni S, Reznek R.

Methods Mol Biol. 2011;727:171-89. doi: 10.1007/978-1-61779-062-1_10.

PMID:
21331934
29.

Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring.

Murray I, Kalemis A, Glennon J, Hasan S, Quraishi S, Beyer T, Avril N.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1643-53. doi: 10.1007/s00259-010-1466-5. Epub 2010 Apr 29.

PMID:
20428866
30.

The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.

Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A.

Int J Urol. 2010 Jun;17(6):501-11. doi: 10.1111/j.1442-2042.2010.02509.x. Epub 2010 Apr 1. Review.

31.

Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT.

Barwick T, Murray I, Megadmi H, Drake WM, Plowman PN, Akker SA, Chew SL, Grossman AB, Avril N.

Eur J Endocrinol. 2010 Jun;162(6):1131-9. doi: 10.1530/EJE-09-1023. Epub 2010 Mar 8.

PMID:
20212015
32.

FDG-PET/CT as a molecular biomarker in ovarian cancer.

Nowosinska E, Avril S, Murray I, Szyszko T, Avril N.

Cancer Biomark. 2010-2011;8(4-5):167-75. doi: 10.3233/CBM-2011-0219. Review.

PMID:
22045351
33.

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.

Dose-Schwarz J, Tiling R, Avril-Sassen S, Mahner S, Lebeau A, Weber C, Schwaiger M, Jänicke F, Untch M, Avril N.

Br J Cancer. 2010 Jan 5;102(1):35-41. doi: 10.1038/sj.bjc.6605427. Epub 2009 Nov 17.

34.

Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.

Barwick T, Bencherif B, Mountz JM, Avril N.

Nucl Med Commun. 2009 Dec;30(12):908-17. doi: 10.1097/MNM.0b013e32832ee93b. Review.

PMID:
19794320
35.

Response to therapy in breast cancer.

Avril N, Sassen S, Roylance R.

J Nucl Med. 2009 May;50 Suppl 1:55S-63S. doi: 10.2967/jnumed.108.057240. Epub 2009 Apr 20. Review.

36.

Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.

Srirangalingam U, Khoo B, Walker L, MacDonald F, Skelly RH, George E, Spooner D, Johnston LB, Monson JP, Grossman AB, Drake WM, Akker SA, Pollard PJ, Plowman N, Avril N, Berney DM, Burrin JM, Reznek RH, Kumar VK, Maher ER, Chew SL.

Endocr Relat Cancer. 2009 Jun;16(2):515-25. doi: 10.1677/ERC-08-0239. Epub 2009 Feb 10.

PMID:
19208735
37.

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.

Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Avril N.

J Clin Oncol. 2009 Feb 1;27(4):535-41. doi: 10.1200/JCO.2008.17.2650. Epub 2008 Dec 15.

PMID:
19075273
38.

Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma.

Jacobs SA, Harrison AM, Swerdlow SH, Foon KA, Avril N, Vidnovic N, Joyce J, DeMonaco N, McCarty KS Jr.

Mol Imaging Biol. 2009 Jan-Feb;11(1):39-45. doi: 10.1007/s11307-008-0170-3. Epub 2008 Sep 5.

PMID:
18773247
39.

Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.

Degirmenci B, Wilson D, Laymon CM, Becker C, Mason NS, Bencherif B, Agarwal A, Luketich J, Landreneau R, Avril N.

Nucl Med Commun. 2008 Jul;29(7):614-22. doi: 10.1097/MNM.0b013e3282f9b5a0.

PMID:
18528183
40.

Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers.

Srirangalingam U, Walker L, Khoo B, MacDonald F, Gardner D, Wilkin TJ, Skelly RH, George E, Spooner D, Monson JP, Grossman AB, Akker SA, Pollard PJ, Plowman N, Avril N, Berney DM, Burrin JM, Reznek RH, Kumar VK, Maher ER, Chew SL.

Clin Endocrinol (Oxf). 2008 Oct;69(4):587-96. doi: 10.1111/j.1365-2265.2008.03274.x. Epub 2008 Apr 14.

PMID:
18419787
41.

123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation.

Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, Avril N, Monson JP, Grossman AB, Reznek RH.

Clin Endocrinol (Oxf). 2008 Aug;69(2):181-8. doi: 10.1111/j.1365-2265.2008.03256.x. Epub 2008 Apr 3.

PMID:
18394016
42.

Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.

Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, Dose-Schwarz J.

Ann Oncol. 2008 Jul;19(7):1249-54. doi: 10.1093/annonc/mdn057. Epub 2008 Mar 19.

PMID:
18356138
43.

Recommendations on the use of 18F-FDG PET in oncology.

Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF.

J Nucl Med. 2008 Mar;49(3):480-508. doi: 10.2967/jnumed.107.047787. Epub 2008 Feb 20.

44.

F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.

Avril N, Adler LP.

Radiol Clin North Am. 2007 Jul;45(4):645-57, vi. Review.

PMID:
17706529
45.

Metabolic FDG-PET imaging in breast cancer: implications for treatment stratification.

Avril N.

Nat Clin Pract Oncol. 2007 Jun;4(6):336-7. Epub 2007 Apr 17. No abstract available.

PMID:
17438577
46.

Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer.

Sassen S, Schmalfeldt B, Avril N, Kuhn W, Busch R, Höfler H, Fend F, Nährig J.

Hum Pathol. 2007 Jun;38(6):926-34. Epub 2007 Mar 30.

PMID:
17397905
47.

Functional PET imaging in cancer drug development.

Avril N, Propper D.

Future Oncol. 2007 Apr;3(2):215-28. Review.

PMID:
17381421
48.

Molecular positron emission tomography and PET/CT imaging in urological malignancies.

Powles T, Murray I, Brock C, Oliver T, Avril N.

Eur Urol. 2007 Jun;51(6):1511-20; discussion 1520-1. Epub 2007 Jan 23. Review.

PMID:
17275167
49.

18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.

Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N.

J Nucl Med. 2007 Feb;48(2):221-6. Erratum in: J Nucl Med. 2007 Mar;48(3):412. Bencherif, Badreddine B [corrected to Bencherif, Badreddine].

50.

Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.

Thrall MM, DeLoia JA, Gallion H, Avril N.

Gynecol Oncol. 2007 Apr;105(1):17-22. Epub 2007 Jan 10.

PMID:
17208284

Supplemental Content

Support Center